Schizophrenia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H2 2018’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Schizophrenia

- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects

- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Schizophrenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Schizophrenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Acadia Pharmaceuticals Inc

Adamed Sp z oo

Aequus Pharmaceuticals Inc

AgeneBio Inc

Alkermes Plc

Athersys Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

BCWorld ...

AbbVie Inc

Acadia Pharmaceuticals Inc

Adamed Sp z oo

Aequus Pharmaceuticals Inc

AgeneBio Inc

Alkermes Plc

Athersys Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

BCWorld Pharm Co Ltd

BioHealthonomics Inc

BioStem Technologies Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cerevance Inc

Concert Pharmaceuticals Inc

Curemark LLC

Daewoong Pharmaceutical Co Ltd

Delpor Inc

Denovo Biopharma LLC

DURECT Corp

F. Hoffmann-La Roche Ltd

Fabre-Kramer Pharmaceuticals Inc

Gabather AB

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GP Pharm SA

GW Pharmaceuticals Plc

H. Lundbeck AS

Heptares Therapeutics Ltd

Hisamitsu Pharmaceutical Co Inc

Impel NeuroPharma Inc

Insys Therapeutics Inc

Intra-Cellular Therapies Inc

IRLAB Therapeutics AB

Johnson & Johnson

Karuna Pharmaceuticals Inc

KemPharm Inc

Laboratorios Farmaceuticos Rovi SA

Lead Discovery Center GmbH

LifeMax Laboratories Inc

Lohocla Research Corp

Luye Pharma Group Ltd

Mapi Pharma Ltd

MedinCell SA

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Neurocrine Biosciences Inc

NeurOp Inc

Newron Pharmaceuticals SpA

Omeros Corp

Otsuka Holdings Co Ltd

Pfizer Inc

Ra Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

SkySea Pharmaceutical Inc

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Ltd

Vanda Pharmaceuticals Inc

Vitality Biopharma Inc

VLP Therapeutics LLC

Zysis Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Schizophrenia – Overview 7

Schizophrenia – Therapeutics Development 8

Schizophrenia – Therapeutics Assessment 23

Schizophrenia – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 6

Schizophrenia – Overview 7

Schizophrenia – Therapeutics Development 8

Schizophrenia – Therapeutics Assessment 23

Schizophrenia – Companies Involved in Therapeutics Development 37

Schizophrenia – Drug Profiles 71

Schizophrenia – Dormant Projects 285

Schizophrenia – Discontinued Products 294

Schizophrenia – Product Development Milestones 297

Appendix 307

List of Tables

List of Tables

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Schizophrenia – Pipeline by AbbVie Inc, H2 2018

Schizophrenia – Pipeline by Acadia Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by Adamed Sp z oo, H2 2018

Schizophrenia – Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by AgeneBio Inc, H2 2018

Schizophrenia – Pipeline by Alkermes Plc, H2 2018

Schizophrenia – Pipeline by Athersys Inc, H2 2018

Schizophrenia – Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by Avineuro Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by BCWorld Pharm Co Ltd, H2 2018

Schizophrenia – Pipeline by BioHealthonomics Inc, H2 2018

Schizophrenia – Pipeline by BioStem Technologies Inc, H2 2018

Schizophrenia – Pipeline by BioXcel Therapeutics Inc, H2 2018

Schizophrenia – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Schizophrenia – Pipeline by Bristol-Myers Squibb Co, H2 2018

Schizophrenia – Pipeline by Cerevance Inc, H2 2018

Schizophrenia – Pipeline by Concert Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by Curemark LLC, H2 2018

Schizophrenia – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Schizophrenia – Pipeline by Delpor Inc, H2 2018

Schizophrenia – Pipeline by Denovo Biopharma LLC, H2 2018

Schizophrenia – Pipeline by DURECT Corp, H2 2018

Schizophrenia – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Schizophrenia – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by Gabather AB, H2 2018

Schizophrenia – Pipeline by Genentech Inc, H2 2018

Schizophrenia – Pipeline by GlaxoSmithKline Plc, H2 2018

Schizophrenia – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Schizophrenia – Pipeline by GP Pharm SA, H2 2018

Schizophrenia – Pipeline by GW Pharmaceuticals Plc, H2 2018

Schizophrenia – Pipeline by H. Lundbeck AS, H2 2018

Schizophrenia – Pipeline by Heptares Therapeutics Ltd, H2 2018

Schizophrenia – Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018

Schizophrenia – Pipeline by Impel NeuroPharma Inc, H2 2018

Schizophrenia – Pipeline by Insys Therapeutics Inc, H2 2018

Schizophrenia – Pipeline by Intra-Cellular Therapies Inc, H2 2018

Schizophrenia – Pipeline by IRLAB Therapeutics AB, H2 2018

Schizophrenia – Pipeline by Johnson & Johnson, H2 2018

Schizophrenia – Pipeline by Karuna Pharmaceuticals Inc, H2 2018

Schizophrenia – Pipeline by KemPharm Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports